Skye Bioscience, Inc., was incorporated in Nevada on March 16, 2011. The company is a clinical-stage biopharmaceutical company with a mission to pioneer the development of new drugs and unlock the pharmaceutical potential of ECS. Their clinical assets focus on the regulation of CB1, providing new treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration (such as obesity and glaucoma).
